Stock Financial Ratios, Dividends, Split History
IVTY / Invuity, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||65.38|
|Enterprise Value ($M)||76.53|
|Book Value ($M)||-0.86|
|Book Value / Share||-0.05|
|Price / Book||-75.84|
|NCAV / Share||-0.53|
|Price / NCAV||-7.13|
|Income Statement (mra) ($M)|
|Balance Sheet (mrq) ($M)|
|Cash & Equivalents||17.96|
|Cash / Share||1.04|
|Common Stock Shares Outstanding||17,179,258|
|Common Shares Outstanding||17,204,000|
|Preferred Stock Shares Outstanding||0|
|Weighted Average Number Of Shares Outstanding Basic||17,051,629|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Cash Conversion Cycle||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-1.41|
|Return on Assets (ROA)||-0.66|
|Return on Equity (ROE)||-1.16|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1393020|
|SIC 3841 - Surgical and Medical Instruments and Apparatus|
Stock splits are used by Invuity, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
Peers - Surgical and Medical Instruments and Apparatus (3841)
AMDA / Amedica Corporation
CASM / CAS Medical Systems, Inc.
CYTX / Cytori Therapeutics, Inc.
DRIO / DarioHealth Corp
DSCI / Derma Sciences, Inc.
GID / GI DYNAMICS, INC.
HART / Harvard Apparatus Regenerative Technology, Inc.
ICAD / icad, inc.
MDXG / MiMedx Group, Inc.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
Related News Stories
* INVUITY INC - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED EXPANSION OF ITS SALES AND MARKETING ACTIVITIES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com) (2-0)
Good day, ladies and gentlemen, and welcome to the Invuity Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (2-1)
Management however is culpable for several failings on capital allocation and cash burn. These issues run deep and effect the company's culture and compensation. (2-2)
Good day, ladies and gentlemen. And welcome to the Invuity 2017 third quarter results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. I would now like to turn the call over to Mr. Mark Klausner with Westwicke Partners. Sir, you may begin. (2-1)
as of ET